Literature DB >> 6863450

Simultaneous determination of amiodarone and its major metabolite desethylamiodarone in plasma, urine and tissues by high-performance liquid chromatography.

T A Plomp, M Engels, E O Robles de Medina, R A Maes.   

Abstract

A simple and sensitive high-performance liquid chromatographic method for the simultaneous assay of amiodarone and desethylamiodarone in plasma, urine and tissues has been developed. The method for plasma samples and tissue samples after homogenizing with 50% ethanol, involves deproteinization with acetonitrile containing the internal standard followed by centrifugation and direct injection of the supernatant into the liquid chromatograph. The method for urine specimens includes extraction with a diisopropyl ether-acetonitrile (95:5, v/v) mixture at pH 7.0 using disposable Clin-Elut 1003 columns, followed by evaporation of the eluate, reconstitution of the residue in methanol-acetonitrile (1:2, v/v) mixture and injection into the chromatograph. Separation was obtained using a Radial-Pak C18 column operating in combination with a radial compression separation unit and a methanol-25% ammonia (99.3:0.7, v/v) mobile phase. A wavelength of 242 nm was used to monitor amiodarone, desethylamiodarone and the internal standard. The influence of the ammonia concentration in the mobile phase on the capacity factors of amiodarone, desethylamiodarone and two other potential metabolites, monoiodoamiodarone (L6355) and desiodoamiodarone (L3937) were investigated. Endogenous substances or a variety of drugs concomitantly used in amiodarone therapy did not interfere with the assay. The limit of sensitivity of the assay was 0.025 micrograms/ml with a precision of +/- 17%. The inter- and intra-day coefficient of variation for replicate analyses of spiked plasma samples was less than 6%. This method has been demonstrated to be suitable for pharmacokinetic and metabolism studies of amiodarone in man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6863450     DOI: 10.1016/s0378-4347(00)80958-5

Source DB:  PubMed          Journal:  J Chromatogr


  6 in total

Review 1.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

2.  Determination of amiodarone hydrochloride in pharmaceutical formulations by derivative UV spectrophotometry and high-performance liquid chromatography (HPLC).

Authors:  A M Di Pietra; V Cavrini; R Gatti; M A Raggi
Journal:  Pharm Res       Date:  1988-11       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

5.  Amiodarone pneumonitis: three further cases with a review of published reports.

Authors:  J I Darmanata; N van Zandwijk; D R Düren; E A van Royen; W J Mooi; T A Plomp; H M Jansen; D Durrer
Journal:  Thorax       Date:  1984-01       Impact factor: 9.139

6.  Uptake of amiodarone by thyroidal and non-thyroidal cell lines.

Authors:  F Bogazzi; F Raggi; F Ultimieri; D Russo; C Cosci; P Cecchetti; E Dell'Unto; C Sardella; M Tonacchera; P Vitti; L Benzi; L Bartalena; E Martino
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.